Controversies in the therapy of early stage breast cancer.

Content Provider	Semantic Scholar
Author	Cianfrocca, Mary E. Gradishar, William John
Copyright Year	2005
Abstract	Breast cancer is the most common malignancy among U.S. women, with more than 200,000 new cases diagnosed annually. In the U.S., mortality from breast cancer has declined in recent years as a result of more widespread screening, leading to earlier detection, as well as advances in the adjuvant treatment of early-stage disease. It is widely accepted that the appropriate use of adjuvant chemotherapy and endocrine therapy improves the disease-free and overall survival of patients with early-stage breast cancer. It is, therefore, standard clinical practice to administer adjuvant systemic therapy to patients with node-positive and high-risk, node-negative breast cancer. There remain, however, many controversies in the primary systemic therapy of breast cancer, which are discussed in this review.
Starting Page	23
Ending Page	32
Page Count	10
File Format	PDF HTM / HTML
Alternate Webpage(s)	http://theoncologist.alphamedpress.org/content/10/10/766.full.pdf
PubMed reference number	16314287v1
Volume Number	10
Issue Number	10
Journal	The oncologist
Language	English
Access Restriction	Open
Subject Keyword	Anatomic Node Aromatase Inhibitors Chemotherapy Regimen Chemotherapy, Adjuvant Conflict (Psychology) Early-Stage Breast Carcinoma Hormone Therapy Importal Limited stage (cancer stage) Lymph Node Tissue Lymphadenopathy Malignant neoplasm of breast Mammary Neoplasms Overall Survival Patients Pharmaceutical Adjuvants Tamoxifen Taxanes ovarian neoplasm systemic therapy
Content Type	Text
Resource Type	Article